FDA Reviews Outdated Guidance Documents - - BioPharm International


FDA Reviews Outdated Guidance Documents

FDA announced that the Center for Drug Evaluation and Research (CDER) has reviewed the status of draft guidance documents issued before 2010 to determine what should be done with those guidance documents going forward. According to the Federal Register, CDER will withdraw guidance documents that are not up to date and lack current information. CDER will determine which guidance documents reflect the agency’s current thinking and either revise or finalize the documents.

In the review, CDER identified 23 draft guidance documents for withdrawal in the areas of CGMP compliance, development of antimicrobial drugs, abbreviated new drug applications (ANDAs), labeling of ANDAs, and more. Guidance documents to be withdrawn include but are not limited to:

  • “Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients”—issued April 1998
  • “Powder Blends and Finished Dosage Units—Stratified In-Process Dosage Unit Sampling and Assessment”—issued November 2003
  • “Forms for Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution”—issued May 2001.
  • “Disclosing Information Provided to Advisory Committees in Connection With Open Advisory Committee Meetings Related to the Testing or Approval of New Drugs and Convened by CDER, Beginning on January 1, 2000”—issued December 1999.
  • “Labeling Over-the-Counter (OTC) Human Drug Products—Updating Labeling in ANDAs”—issued February 2001.
  • “Inhalation Drug Products Packaged in Semipermeable Container Closure Systems”—issued July 2002.

CDER has identified guidance documents in the following topics and are developing a plan for revision or finalization:

  • Biopharmaceutics
  • Chemistry, manufacturing, and controls
  • Clinical pharmacology
  • Combination products
  • CGMP compliance
  • Development of antimicrobial drugs
  • Drug advertisements
  • Drug safety
  • Electronic submissions
  • Labeling
  • OTC products
  • Pharmacology and toxicology
  • Procedural guidance
  • Radiopharmaceuticals.

More information on the withdrawal, revision, and finalization of these guidance documents can be found on CDER’s website.

Source: Federal Register

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here